• New Hire: David Sharp, US Business Development Lead.

    A very warm welcome to the newest member of the PBC Biomed team David Sharp, who has just joined as our US Business Development lead. David spent some time in our Irish headquarters this week to meet the extended team, however he will be based out of our US office at Epicenter Memphis. During his 25+ years working within…

    Read More...

  • ESTROT 2024

    ,

    PBC Biomed will be exhibiting at the 8th annual ESTROT Congress in Helsinki, Finland from 10-12th June. This year, the programme focuses on: Event information and registration is available here: https://www.estrot.org/eighth-estrot-congress-24.php

    Read More...

  • OTA Annual Congress 2024

    ,

    Part 3 of the PBC Biomed ‘Provisional Fixation’ Education Programme is scheduled to air at the OTA annual conference in Montreal, Canada. Our global panel of surgeon advisors will offer further insight on the future of ‘Provisional Fixation’ and the role of our new #breakthroughdevice OsStic® in changing the outlook on patient treatment. The conference…

    Read More...

  • OMTEC 2024

    ,

    Join us in Chicago for the 2024 OMTEC event, which will provide an opportunity to connect with some of our key R&D and commercial team members. The theme of this year’s event is ‘Educate. Connect. Empower.’ More information on the event is available here: https://omtecexpo.com/

    Read More...

  • ODT Forum 2024

    ,

    Our US-based PBC Biomed team members will attend the ODT meeting in Memphis this year, a little over a year on from opening the first US office location. This is the first time PBC Biomed will be exhibiting at the event – we look forward to another opportunity to rub shoulders with the ever-evolving Memphis…

    Read More...

  • PBC Biomed Events & Education Programme 2024

    , , ,

    PBC Biomed executed an extensive education programme in 2023 – some key moments are captured in the image below! As well as offering exciting updates on the development of our technologies, the programme also facilitated meaningful engagement with our industry, research and clinician networks. At the American Academy of Orthopaedic Surgeons (AAOS) Conference in March (Las Vegas), we…

    Read More...

  • PBC Biomed had the pleasure of hosting our Clinical Advisory Board at the Medical Education & Research Institute in Memphis last week, for a development lab focused on OsStic®.

    ,

    The feedback and insights shared by this group are critical in supporting our development and educational objectives for OsStic®, which was recently awarded #BreakthroughDevice Designation. The group also looked at our other innovation programmes, including a #disruptive technology focused on nerve repair, as well as multiple new hardware concepts. Our R&D team have been working closely with our surgeon…

    Read More...

  • FDA grants global Medical Device company Biomimetic Innovations ‘Breakthrough Device’ designation for OsStic® Synthetic Injectable Structural Bio-Adhesive Bone Void Filler. 

    , , ,

    Shannon, Ireland, 19th January, 2024: Biomimetic Innovations Ltd today announced that OsStic® has been granted ‘Breakthrough Device’ designation by the FDA. The proposed indication statement for this novel new technology is; ” OsStic®Synthetic Injectable Bone Void Filler is a structural, mechanically enhanced bioadhesive for reduction, provisional fixation, or void filling of peri-articular fractures or defects…

    Read More...

  • ASPN-AAHS-ASRM meetings kick off 2024 Conference Season for PBC Biomed

    Brittney Martinez, VP of Business Development and Marketing and Gerard Insley, Chief Science Officer are pictured at the ASPN, AAHS and ASRM joint meeting in Nassau last week. This meeting provided an excellent opportunity for the team to connect with surgeon advisors, industry partners and current clients ahead of an exciting year. Update to follow…

    Read More...

  • 2024: A Transformative Year Ahead for PBC Biomed

    Driven by our dedicated team as well as our valued industry and academic partners, 2024 is set to become a transformative year for our commercialisation and developmental programmes. We would like to take this opportunity to thank our current partners and friends for your continued support and encouragement – we look forward to sharing further…

    Read More...